Pelareorep

Oncolytics Biotech® Presents Updated Clinical Data at SITC Annual Meeting Showing a 69% Objective Response Rate and Confirmed Complete Response in GOBLET Study's Pancreatic Cancer Cohort

Retrieved on: 
Thursday, November 10, 2022
Lymphatic system, Forward-looking statement, 2012 Vuelta a España, Stage 1 to Stage 11, ONC, DKG, Convention center, Pancreatic cancer, MPH, University of Ulm, PDAC, Annual general meeting, Interim, Immunotherapy, Research, Neoplasm, Travel, Boston Convention and Exhibition Center, KOL, COVID-19, Beth Israel Deaconess Medical Center, Goblet cell, Cancer, CEACAM6, PD-L1, NASDAQ, Pelareorep, Patient, Safety, Securities Exchange Act of 1934, Time, Oncology, Biomarker, Company, Science, AB, Clinical trial, Stage 2, Poster, Society for Immunotherapy of Cancer, Biotechnology, TSX, DOI, CBR, LINK, ORR, Phenotype, Regulation, SITC, AIO, Pharmaceutical industry, Risk management, Medical imaging, Oncolytics Biotech

SAN DIEGO, Calif and CALGARY, AB, Nov. 10, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced updated results from the phase 1/2 GOBLET study's first-line advanced/metastatic pancreatic ductal adenocarcinoma (PDAC) cohort. Patients in this cohort are treated with the combination of pelareorep, Roche's anti-PD-L1 checkpoint inhibitor atezolizumab, and the chemotherapeutic agents gemcitabine and nab-paclitaxel. The updated data are featured in a poster presentation at the ongoing Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, which is taking place both virtually and in-person at the Boston Convention and Exhibition Center in Boston, MA.  

Key Points: 
  • (NASDAQ: ONCY) (TSX: ONC) today announced updated results from the phase 1/2 GOBLET study's first-line advanced/metastatic pancreatic ductal adenocarcinoma (PDAC) cohort.
  • Patients in this cohort are treated with the combination of pelareorep, Roche's anti-PD-L1 checkpoint inhibitor atezolizumab, and the chemotherapeutic agents gemcitabine and nab-paclitaxel.
  • Objective response rate (ORR) and clinical benefit rate (CBR) in GOBLET's PDAC cohort (n=13) were 69% and 85%, respectively, asof the SITC poster's data cutoff date (October 12, 2022).
  • We were particularly excited to see a partial response deepen into a confirmed complete response as of the latest data cut, since this further indicates potentially durable anti-cancer effects from the combination therapy."

Oncolytics Biotech® Presents Updated Clinical Data at SITC Annual Meeting Showing a 69% Objective Response Rate and Confirmed Complete Response in GOBLET Study's Pancreatic Cancer Cohort

Retrieved on: 
Thursday, November 10, 2022
Lymphatic system, Forward-looking statement, 2012 Vuelta a España, Stage 1 to Stage 11, ONC, DKG, Convention center, Pancreatic cancer, MPH, University of Ulm, PDAC, Annual general meeting, Interim, Immunotherapy, Research, Neoplasm, Travel, Boston Convention and Exhibition Center, KOL, COVID-19, Beth Israel Deaconess Medical Center, Goblet cell, Cancer, CEACAM6, PD-L1, NASDAQ, Pelareorep, Patient, Safety, Securities Exchange Act of 1934, Time, Oncology, Biomarker, Company, Science, AB, Clinical trial, Stage 2, Poster, Society for Immunotherapy of Cancer, Biotechnology, TSX, DOI, CBR, LINK, ORR, Phenotype, Regulation, SITC, AIO, Pharmaceutical industry, Risk management, Medical imaging, Oncolytics Biotech

SAN DIEGO, Calif and CALGARY, AB, Nov. 10, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced updated results from the phase 1/2 GOBLET study's first-line advanced/metastatic pancreatic ductal adenocarcinoma (PDAC) cohort. Patients in this cohort are treated with the combination of pelareorep, Roche's anti-PD-L1 checkpoint inhibitor atezolizumab, and the chemotherapeutic agents gemcitabine and nab-paclitaxel. The updated data are featured in a poster presentation at the ongoing Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, which is taking place both virtually and in-person at the Boston Convention and Exhibition Center in Boston, MA.  

Key Points: 
  • (NASDAQ: ONCY) (TSX: ONC) today announced updated results from the phase 1/2 GOBLET study's first-line advanced/metastatic pancreatic ductal adenocarcinoma (PDAC) cohort.
  • Patients in this cohort are treated with the combination of pelareorep, Roche's anti-PD-L1 checkpoint inhibitor atezolizumab, and the chemotherapeutic agents gemcitabine and nab-paclitaxel.
  • Objective response rate (ORR) and clinical benefit rate (CBR) in GOBLET's PDAC cohort (n=13) were 69% and 85%, respectively, asof the SITC poster's data cutoff date (October 12, 2022).
  • We were particularly excited to see a partial response deepen into a confirmed complete response as of the latest data cut, since this further indicates potentially durable anti-cancer effects from the combination therapy."

Oncolytics Biotech® Reports Interim Results from Phase 1/2 GOBLET Study Showing a 70% Objective Response Rate in Pancreatic Cancer at the SITC Annual Meeting

Retrieved on: 
Monday, November 7, 2022
Lymphatic system, Science, International, Boston Convention and Exhibition Center, DKG, Pelareorep, Stage 2, AIO, Securities Exchange Act of 1934, Interim, Travel, Clinical trial, DOI, SITC, Convention center, Company, Neoplasm, Journal, Immunotherapy, TSX, Phenotype, Cancer, Forward-looking statement, AB, Society, Patient, ORR, Investor relations, Progression-free survival, Research, CEACAM6, KOL, PDAC, LINK, Biotechnology, Breast, COVID-19, Annual general meeting, Pancreatic cancer, 2012 Vuelta a España, Stage 1 to Stage 11, Survival, Society for Immunotherapy of Cancer, MSI, Anal cancer, Time, JITC, Goblet cell, Safety, Biomarker, ONC, Poster, Standard of care, Regulation, NASDAQ, Roche, Oncology, Birth control, Pharmaceutical industry, Medical imaging, Oncolytics Biotech

(NASDAQ: ONCY) (TSX: ONC) today reported interim results from the phase 1/2 GOBLET study's first-line advanced/metastatic pancreatic ductal adenocarcinoma (PDAC) cohort in an abstract published as part of the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting.

Key Points: 
  • (NASDAQ: ONCY) (TSX: ONC) today reported interim results from the phase 1/2 GOBLET study's first-line advanced/metastatic pancreatic ductal adenocarcinoma (PDAC) cohort in an abstract published as part of the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting.
  • "Further, PD-(L)1 inhibitors only benefit fewer than one percent of pancreatic cancer patients classified as MSI-high.
  • Dr. Matt Coffey, President and Chief Executive Officer of Oncolytics Biotech Inc., commented, "GOBLET's interim results represent a crucial clinical milestone, providing robust proof-of-concept in a difficult-to-treat indication.
  • Alongside this potential PDAC opportunity, Oncolytics continues to advance pelareorep towards a registration study in metastatic breast cancer.

Oncolytics Biotech® Reports Interim Results from Phase 1/2 GOBLET Study Showing a 70% Objective Response Rate in Pancreatic Cancer at the SITC Annual Meeting

Retrieved on: 
Monday, November 7, 2022
Lymphatic system, Science, International, Boston Convention and Exhibition Center, DKG, Pelareorep, Stage 2, AIO, Securities Exchange Act of 1934, Interim, Travel, Clinical trial, DOI, SITC, Convention center, Company, Neoplasm, Journal, Immunotherapy, TSX, Phenotype, Cancer, Forward-looking statement, AB, Society, Patient, ORR, Investor relations, Progression-free survival, Research, CEACAM6, KOL, PDAC, LINK, Biotechnology, Breast, COVID-19, Annual general meeting, Pancreatic cancer, 2012 Vuelta a España, Stage 1 to Stage 11, Survival, Society for Immunotherapy of Cancer, MSI, Anal cancer, Time, JITC, Goblet cell, Safety, Biomarker, ONC, Poster, Standard of care, Regulation, NASDAQ, Roche, Oncology, Birth control, Pharmaceutical industry, Medical imaging, Oncolytics Biotech

(NASDAQ: ONCY) (TSX: ONC) today reported interim results from the phase 1/2 GOBLET study's first-line advanced/metastatic pancreatic ductal adenocarcinoma (PDAC) cohort in an abstract published as part of the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting.

Key Points: 
  • (NASDAQ: ONCY) (TSX: ONC) today reported interim results from the phase 1/2 GOBLET study's first-line advanced/metastatic pancreatic ductal adenocarcinoma (PDAC) cohort in an abstract published as part of the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting.
  • "Further, PD-(L)1 inhibitors only benefit fewer than one percent of pancreatic cancer patients classified as MSI-high.
  • Dr. Matt Coffey, President and Chief Executive Officer of Oncolytics Biotech Inc., commented, "GOBLET's interim results represent a crucial clinical milestone, providing robust proof-of-concept in a difficult-to-treat indication.
  • Alongside this potential PDAC opportunity, Oncolytics continues to advance pelareorep towards a registration study in metastatic breast cancer.

Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights

Retrieved on: 
Thursday, October 27, 2022
Biotechnology, Phenotype, Time, Cancer, Travel, Forward-looking statement, Lymphatic system, COVID-19, Clinical trial, Securities Exchange Act of 1934, Company, Pelareorep, Research, Neoplasm, Regulation, International, Pharmaceutical industry, Oncolytics Biotech

SAN DIEGO, Calif. and CALGARY, AB, Oct. 27, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a conference call and webcast on Monday, November 7, 2022, at 8:30 a.m. ET to discuss a corporate update and financial results for the third quarter of 2022.

Key Points: 
  • Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent.
  • Such forward-looking statements involve known and unknown risks and uncertainties, which could cause Oncolytics' actual results to differ materially from those in the forward-looking statements.
  • It is unknown whether and how Oncolytics may be affected if the COVID-19 pandemic persists for an extended period of time.
  • The Company does not undertake any obligation to update these forward-looking statements, except as required by applicable laws.

Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights

Retrieved on: 
Thursday, October 27, 2022
Biotechnology, Phenotype, Time, Cancer, Travel, Forward-looking statement, Lymphatic system, COVID-19, Clinical trial, Securities Exchange Act of 1934, Company, Pelareorep, Research, Neoplasm, Regulation, International, Pharmaceutical industry, Oncolytics Biotech

SAN DIEGO, Calif. and CALGARY, AB, Oct. 27, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a conference call and webcast on Monday, November 7, 2022, at 8:30 a.m. ET to discuss a corporate update and financial results for the third quarter of 2022.

Key Points: 
  • Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent.
  • Such forward-looking statements involve known and unknown risks and uncertainties, which could cause Oncolytics' actual results to differ materially from those in the forward-looking statements.
  • It is unknown whether and how Oncolytics may be affected if the COVID-19 pandemic persists for an extended period of time.
  • The Company does not undertake any obligation to update these forward-looking statements, except as required by applicable laws.

Oncolytics Biotech® Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 37th Annual Meeting

Retrieved on: 
Wednesday, October 5, 2022
Time, Pancreatic cancer, ONC, Neoplasm, TSX, SITC, NASDAQ, Patient, Biotechnology, Phenotype, Research, Annual general meeting, Cancer, Immunotherapy, Convention center, Stage 2, Boston Convention and Exhibition Center, Company, Society, Pelareorep, ORR, Securities Exchange Act of 1934, 2012 Vuelta a España, Stage 1 to Stage 11, Safety, 2021 Essex County Council election, KOL, Clinical trial, CEACAM6, Forward-looking statement, Lymphatic system, Travel, COVID-19, AB, Society for Immunotherapy of Cancer, Biomarker, Poster, Regulation, Pharmaceutical industry, Communications satellite, Interior design, Medical imaging, Oncolytics Biotech

SAN DIEGO, and CALGARY, AB, Oct. 5, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the acceptance of two abstracts for poster presentations at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, which is taking place both virtually and in-person at the Boston Convention and Exhibition Center in Boston, MA, from November 8 – 12, 2022.

Key Points: 
  • (NASDAQ: ONCY) (TSX: ONC) today announced the acceptance of two abstracts for poster presentations at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, which is taking place both virtually and in-person at the Boston Convention and Exhibition Center in Boston, MA, from November 8 12, 2022.
  • Additional details on the abstracts and corresponding poster presentations are shown below.
  • Investors should consult Oncolytics' quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements.
  • The Company does not undertake any obligation to update these forward-looking statements, except as required by applicable laws.

Oncolytics Biotech® Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 37th Annual Meeting

Retrieved on: 
Wednesday, October 5, 2022
Time, Pancreatic cancer, ONC, Neoplasm, TSX, SITC, NASDAQ, Patient, Biotechnology, Phenotype, Research, Annual general meeting, Cancer, Immunotherapy, Convention center, Stage 2, Boston Convention and Exhibition Center, Company, Society, Pelareorep, ORR, Securities Exchange Act of 1934, 2012 Vuelta a España, Stage 1 to Stage 11, Safety, 2021 Essex County Council election, KOL, Clinical trial, CEACAM6, Forward-looking statement, Lymphatic system, Travel, COVID-19, AB, Society for Immunotherapy of Cancer, Biomarker, Poster, Regulation, Pharmaceutical industry, Communications satellite, Interior design, Medical imaging, Oncolytics Biotech

SAN DIEGO, and CALGARY, AB, Oct. 5, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the acceptance of two abstracts for poster presentations at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, which is taking place both virtually and in-person at the Boston Convention and Exhibition Center in Boston, MA, from November 8 – 12, 2022.

Key Points: 
  • (NASDAQ: ONCY) (TSX: ONC) today announced the acceptance of two abstracts for poster presentations at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, which is taking place both virtually and in-person at the Boston Convention and Exhibition Center in Boston, MA, from November 8 12, 2022.
  • Additional details on the abstracts and corresponding poster presentations are shown below.
  • Investors should consult Oncolytics' quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements.
  • The Company does not undertake any obligation to update these forward-looking statements, except as required by applicable laws.

Oncolytics Biotech® Reports Second Quarter 2022 Financial Results and Recent Operational Highlights

Retrieved on: 
Thursday, August 11, 2022
TME, ESMO, Merck Group, Trillium, Survival, Oncolytics Biotech, ONC, Risk, CAR, Letrozole, AB, Breast, 2005 Tour de France, Stage 1 to Stage 11, Breast cancer, Mouse, Neoplasm, Industry, CFO, Cancer, Brain, TSX, Poster, European Society for Medical Oncology, Pfizer, Merck, PR, Patient, Pelareorep, Roche, Therapy, International, Company, Darmstadt, Prognosis, Acquisition, Pancreatic cancer, Data, Paclitaxel, NASDAQ, LINK, Skin cancer, Science Translational Medicine, Oncology, Progression-free survival, Immune system, Investor relations, Medical imaging, Pharmaceutical industry, Video game

(NASDAQ: ONCY) (TSX: ONC) today announced recent operational highlights and financial results for the second quarter ended June 30, 2022.

Key Points: 
  • (NASDAQ: ONCY) (TSX: ONC) today announced recent operational highlights and financial results for the second quarter ended June 30, 2022.
  • Operating expense for the second quarter of 2022 was $2.8 million, compared to $3.5 million for the second quarter of 2021.
  • R&D expense for the second quarter of 2022 was $3.2 million, compared to $3.2 million for the second quarter of 2021.
  • Net cash used in operating activities for the second quarter of 2022 was $6.9 million, compared to $6.8 million in the second quarter of 2021.

Oncolytics Biotech® Reports Second Quarter 2022 Financial Results and Recent Operational Highlights

Retrieved on: 
Thursday, August 11, 2022
TME, ESMO, Merck Group, Trillium, Survival, Oncolytics Biotech, ONC, Risk, CAR, Letrozole, AB, Breast, 2005 Tour de France, Stage 1 to Stage 11, Breast cancer, Mouse, Neoplasm, Industry, CFO, Cancer, Brain, TSX, Poster, European Society for Medical Oncology, Pfizer, Merck, PR, Patient, Pelareorep, Roche, Therapy, International, Company, Darmstadt, Prognosis, Acquisition, Pancreatic cancer, Data, Paclitaxel, NASDAQ, LINK, Skin cancer, Science Translational Medicine, Oncology, Progression-free survival, Immune system, Investor relations, Medical imaging, Pharmaceutical industry, Video game

(NASDAQ: ONCY) (TSX: ONC) today announced recent operational highlights and financial results for the second quarter ended June 30, 2022.

Key Points: 
  • (NASDAQ: ONCY) (TSX: ONC) today announced recent operational highlights and financial results for the second quarter ended June 30, 2022.
  • Operating expense for the second quarter of 2022 was $2.8 million, compared to $3.5 million for the second quarter of 2021.
  • R&D expense for the second quarter of 2022 was $3.2 million, compared to $3.2 million for the second quarter of 2021.
  • Net cash used in operating activities for the second quarter of 2022 was $6.9 million, compared to $6.8 million in the second quarter of 2021.